These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 25645011

  • 1. The delay time in sickle cell disease after 40 years: A paradigm assessed.
    Ferrone FA.
    Am J Hematol; 2015 May; 90(5):438-45. PubMed ID: 25645011
    [Abstract] [Full Text] [Related]

  • 2. Quantitative prediction of erythrocyte sickling for the development of advanced sickle cell therapies.
    Lu L, Li Z, Li H, Li X, Vekilov PG, Karniadakis GE.
    Sci Adv; 2019 Aug; 5(8):eaax3905. PubMed ID: 31457104
    [Abstract] [Full Text] [Related]

  • 3. New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo?
    Oder E, Safo MK, Abdulmalik O, Kato GJ.
    Br J Haematol; 2016 Oct; 175(1):24-30. PubMed ID: 27605087
    [Abstract] [Full Text] [Related]

  • 4. Exposure of blood from patients with sickle cell disease to air changes the morphological, oxygen-binding, and sickling properties of sickled erythrocytes.
    Obata K, Mattiello J, Asakura K, Ohene-Frempong K, Asakura T.
    Am J Hematol; 2006 Jan; 81(1):26-35. PubMed ID: 16369974
    [Abstract] [Full Text] [Related]

  • 5. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease.
    Oksenberg D, Dufu K, Patel MP, Chuang C, Li Z, Xu Q, Silva-Garcia A, Zhou C, Hutchaleelaha A, Patskovska L, Patskovsky Y, Almo SC, Sinha U, Metcalf BW, Archer DR.
    Br J Haematol; 2016 Oct; 175(1):141-53. PubMed ID: 27378309
    [Abstract] [Full Text] [Related]

  • 6. Targeting HbS Polymerization.
    Ferrone FA.
    Semin Hematol; 2018 Apr; 55(2):53-59. PubMed ID: 30616807
    [Abstract] [Full Text] [Related]

  • 7. Sickle cell vaso-occlusion.
    Fabry ME, Kaul DK.
    Hematol Oncol Clin North Am; 1991 Jun; 5(3):375-98. PubMed ID: 1864816
    [Abstract] [Full Text] [Related]

  • 8. Delay time of hemoglobin S polymerization prevents most cells from sickling in vivo.
    Mozzarelli A, Hofrichter J, Eaton WA.
    Science; 1987 Jul 31; 237(4814):500-6. PubMed ID: 3603036
    [Abstract] [Full Text] [Related]

  • 9. Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors.
    Okam MM, Ebert BL.
    Expert Rev Hematol; 2012 Jun 31; 5(3):303-11. PubMed ID: 22780210
    [Abstract] [Full Text] [Related]

  • 10. Established and experimental treatments for sickle cell disease.
    De Franceschi L, Corrocher R.
    Haematologica; 2004 Mar 31; 89(3):348-56. PubMed ID: 15020275
    [Abstract] [Full Text] [Related]

  • 11. In vitro exposure to hydroxyurea reduces sickle red blood cell deformability.
    Huang Z, Louderback JG, King SB, Ballas SK, Kim-Shapiro DB.
    Am J Hematol; 2001 Jul 31; 67(3):151-6. PubMed ID: 11391710
    [Abstract] [Full Text] [Related]

  • 12. Polymerization of sickle cell hemoglobin at arterial oxygen saturation impairs erythrocyte deformability.
    Green MA, Noguchi CT, Keidan AJ, Marwah SS, Stuart J.
    J Clin Invest; 1988 Jun 31; 81(6):1669-74. PubMed ID: 3384944
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Kinetics of increased deformability of deoxygenated sickle cells upon oxygenation.
    Huang Z, Hearne L, Irby CE, King SB, Ballas SK, Kim-Shapiro DB.
    Biophys J; 2003 Oct 31; 85(4):2374-83. PubMed ID: 14507701
    [Abstract] [Full Text] [Related]

  • 16. Rapid and reproducible characterization of sickling during automated deoxygenation in sickle cell disease patients.
    Rab MAE, van Oirschot BA, Bos J, Merkx TH, van Wesel ACW, Abdulmalik O, Safo MK, Versluijs BA, Houwing ME, Cnossen MH, Riedl J, Schutgens REG, Pasterkamp G, Bartels M, van Beers EJ, van Wijk R.
    Am J Hematol; 2019 May 31; 94(5):575-584. PubMed ID: 30784099
    [Abstract] [Full Text] [Related]

  • 17. Intracellular polymerization of sickle hemoglobin: disease severity and therapeutic goals.
    Noguchi CT, Rodgers GP, Schechter AN.
    Prog Clin Biol Res; 1987 May 31; 240():381-91. PubMed ID: 3615501
    [Abstract] [Full Text] [Related]

  • 18. Should we still be focused on red cell hemoglobin F as the principal explanation for the salutary effect of hydroxyurea in sickle cell disease?
    Segel GB, Simon W, Lichtman MA.
    Pediatr Blood Cancer; 2011 Jul 15; 57(1):8-9. PubMed ID: 21480473
    [No Abstract] [Full Text] [Related]

  • 19. Effect of piracetam on sickle erythrocytes and sickle hemoglobin.
    Asakura T, Ohnishi ST, Adachi K, Ozguc M, Hashimoto K, Devlin MT, Schwartz E.
    Biochim Biophys Acta; 1981 May 29; 668(3):397-405. PubMed ID: 7236716
    [Abstract] [Full Text] [Related]

  • 20. Exercise limitation, exercise testing and exercise recommendations in sickle cell anemia.
    Connes P, Machado R, Hue O, Reid H.
    Clin Hemorheol Microcirc; 2011 May 29; 49(1-4):151-63. PubMed ID: 22214686
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.